References
- Goodin DS, Frohman EM, Garmany GP, Jr., et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics And Technology Assessment Subcommittee of The American Academy Of Neurology and the MS Council For Clinical Practice Guidelines. Neurology 2002; 58: 169–178
- Koike F, Satoh J, Miyake S, et al. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J Neuroimmunol 2003; 139: 109–118
- Weinstock-Guttman B, Badgett D, Patrick K, et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 2003; 171: 2694–2702
- Yang, IV, Chen E, Hasseman JP, et al. Within the fold: Assessing differential expression measures and reproducibility in microarray assays. Genome Biol 2002; 3, research0062
- Sturzebecher S, Wandinger KP, Rosenwald A, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003; 126: 1419–1429
- Byskosh PV, Reder AT. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler 1996; 1: 262–269
- Byrnes AA, McArthur JC, Karp CL. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol 2002; 51: 165–174
- Bertram EM, Hawley RG, Watts TH. Overexpression of rab7 enhances the kinetics of antigen processing and presentation with MHC class II molecules in B cells. Int Immunol 2002; 14: 309–318
- Skundric DS, Dai R, Zakarian VL, et al. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE. J Neurosci Res 2005; 79: 680–693
- Wandinger KP, Sturzebecher CS, Bielekova B, et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001; 50: 349–357
- Fainardi E, Rizzo R, Melchiorri L, et al. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy. J Neuroimmunol 2004; 148: 206–211
- Negro F, Baldi M, Mondardini A, et al. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 1994; 107: 479–485